The International Vaccine Institute (IVI) said that it has signed a memorandum of understanding with Sweden’s Ministry for Foreign Affairs to establish its regional office in Stockholm.With the opening of the new office, IVI aims to create an international hub for global health research, innovation,
Hanmi Pharmaceutical said that the European Medicines Agency (EMA) has granted the orphan drug designation (ODD) to its LAPS Triple Agonist (HM15211) for treating primary sclerosing cholangitis.The ODD designation comes after the company received the ODD designation for HM1521 for treating primary b
Hugel, a medical aesthetic company, said Friday that the Ministry of Trade, Industry and Energy (MOTIE) has approved its cross-border merger and acquisition (M&A) in the form of changes in its largest shareholder.On Aug. 24, the company announced that Leguh Issuer Designated Activity Company, its la
Korea’s botulinum toxin (BTX) exports to the United States this year totaled about 34 billion won ($28.7 million), nearly doubling that of 2020.Korea’s BTX shipments to the U.S. have steadily increased since Daewoong Pharmaceutical started exporting Nabota (U.S. product name: Jeuveau) in 2019Accordi
Daewoong Pharmaceutical and Jeil Pharmaceutical are speeding up the development of potassium-competitive acid blocker (P-CAB) drugs for gastroesophageal reflux disease (GERD) to challenge inno.N’s lead with K-Cab (tegoprazan) in the P-CAB market.Both Daewoong and Jeil predict the P-CAB market will g
ATLANTA, Ga. – By Kim Yun-mi/Korea Biomedical Review correspondent - Roche’s Polivy (polatuzumab vedotin) lowered the risk of disease progression, relapse, and death by 27 percent compared to R-CHOP, which has been the standard of care for 20 years in diffuse large B cell lymphoma (DLBCL). The findi
JW Pharmaceutical said that LEO Pharma, its Denmark-based partner, has started the global phase 2b clinical trial of JW1601, an oral atopic dermatitis treatment.The clinical trial aims to evaluate the efficacy and safety of JW1601 by comparing the drug with a placebo in adults with moderate to sever
Korea United Pharm’s discussion for licensing out a polo-like kinase-1 (PLK-1) targeting anticancer drug to a U.S. company stalled for a year.The company said in December 2020 that it was in talks with a U.S. anticancer drug developer to transfer the technology of the PLK-1 inhibitor derived from a
ATLANTA, Ga. – By Kim Yun-mi/Korea Biomedical Review correspondent - Novartis said it shortened the time of manufacturing CAR-T cell therapy from one month to two days. With the new technology, an investigational CAR-T cell therapy YTB323 raised the response rate and complete remission (CR) rate to
In a public filing on Monday, Hugel said that it would purchase its 30 billion won ($25.3 million) treasury stock through a trust contract and retire them. The contract ends on June 13, 2022, and Samsung Securities will sign the contract.The botulinum toxin (BTX) maker plans to retire 100,000 treasu
Celltrion said it increased the supply of its Covid-19 antigen test kits for the U.S. market.The company said that the expanded shipments resulted from the recent U.S. emergency use authorization (EUA) for the general public’s use of the device and an increase in Covid-19 testing amid relaxed social
AstraZeneca said Tuesday that it would expand biopharmaceutical contract manufacturing organization (CMO) business with Samsung Biologics to produce Covid-19 antibody complexes and immunotherapy in Korea.Under the accord, Samsung Biologics will produce AstraZeneca's long-acting Covid-19 antibody com
Moderna’s Covid-19 vaccine manufactured by Samsung Biologics won the regulatory nod, raising the prospect for a stable supply of Covid-19 vaccines in the Korean market.The Ministry of Food and Drug Safety said on Monday that it decided to grant the permit for Spike Inj., after reviewing the applicat
GC has signed a $48.9 million contract with Pan American Health Organization (PAHO) to supply influenza vaccines to Latin America.The company said it is the largest export deal since GC secured PAHO bidding qualifications in 2011, marking a 22 percent increase from the influenza vaccine export to La
Korean pharmaceutical and biotech companies are using new strategies to tackle Covid-19 in the long term.One company began to work with foreign partner firms to develop a new Covid-19 treatment while another narrowed down indications of an existing investigational drug.Most local drugmakers focus on
Boehringer Ingelheim and Eli Lilly are strengthening their position in the Korean heart failure treatment market by winning new indications for Jardiance (ingredient: empagliflozin), a Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor drug.Jardiance played a key role in expanding the treatment area
GC announced on Thursday that it stopped the discussion on the contract manufacturing organization (CMO) agreement on Janssen's Covid-19 vaccine.In August, some media outlets reported that GC discussed a CMO agreement with Janssen for the latter's Covid-19 vaccine. However, the company has since sai
Samsung Pharm said it would withdraw its hotel business, which it started in 2020. Instead, the company said it would sell the land, planned for hotel construction to secure financial liquidity.The company sold the land to GemVax Zio, a subsidiary of GemVax & KAEL.In a public filing on Thursday, Sam
Koreans with acromegaly will likely experience more difficulties as they lose one of the two available second-line treatments.According to industry sources, the supply of Signifor Lar, an acromegaly treatment, has recently stopped. The halt in supply comes after Novartis, the original developer of t
SAN ANTONIO, Texas -- By Kim Yun-mi/Korea Biomedical correspondent - Novartis said its CDK4.6 inhibitor Kisqali (ingredient: ribociclib) improved overall survival (OS) across subtypes of metastatic hormone receptor-positive breast cancer, according to results of phase 3 MONALEESA studies presented a